Evaluation of the rivastigmine role against botulinum toxin-A-induced osteoporosis in albino rats: A biochemical, histological, and immunohistochemical study
The present study aimed to evaluate the role of rivastigmine against the effect of a single unilateral botulinum toxin-A (BTX-A) injection on the bone and bone marrow of adult albino rats 4 weeks after injection. Twenty-four Wistar albino rats were divided into four equal groups: group I, which rece...
Gespeichert in:
| Veröffentlicht in: | Human & experimental toxicology 2018-12, Vol.37 (12), p.1323-1335 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1335 |
|---|---|
| container_issue | 12 |
| container_start_page | 1323 |
| container_title | Human & experimental toxicology |
| container_volume | 37 |
| creator | Ali, DM Abdelzaher, WY Abdel-Hafez, SMN |
| description | The present study aimed to evaluate the role of rivastigmine against the effect of a single unilateral botulinum toxin-A (BTX-A) injection on the bone and bone marrow of adult albino rats 4 weeks after injection. Twenty-four Wistar albino rats were divided into four equal groups: group I, which received distilled water; group II, which received rivastigmine (0.3 mg/kg daily, intraperitoneally for 4 weeks); group III, which received BTX-A (4 IU in 0.2 mL physiological saline) single dose, intramuscularly; and group IV, which received BTX-A + rivastigmine. The results revealed that BTX-A induced a significant decrease in the calcium level with a significant increase in the phosphorus, alkaline phosphatase, C-reactive protein, and tumor necrosis factor α levels in serum. Furthermore, a significant increase in malondialdehyde with a significant decrease in reduced glutathione activities in both bone and bone marrow. Histologically, a distortion and thinning out of the compact bone and trabeculae of cancellous bone of the rat femur in the BTX-A group with an increase in adipocytes in adjacent bone marrow were detected. Immunohistochemically, Cluster of Differentiation 68 (CD68) showed a significant increase in both osteoclasts and bone marrow macrophage. Rivastigmine treatment could relieve the toxic effects induced by BTX-A. In conclusion, rivastigmine has a protective effect against the hazardous effects of BTX-A on bone and bone marrow. |
| doi_str_mv | 10.1177/0960327118774941 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_miscellaneous_2036792313</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0960327118774941</sage_id><sourcerecordid>2036792313</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-b1aec2f7694398317f3d66fe088459ddd861c6af7a9589ed847af8c36fb384f33</originalsourceid><addsrcrecordid>eNp1kU1P3DAQhi3UqizQO6fKUi89NK0_En9wWyFKkZC4lHPk-GPXyLGX2Eblx_S_NmGhlZA4jWbmmXdG8wJwitE3jDn_jiRDlHCMBeetbPEBWOGW8wZJRN-B1dJulv4hOMr5DiHEZIc_gEMiOZWkIyvw5-JBhaqKTxEmB8vWwsk_qFz8ZvRxTlKwUG2Uj7nAIZUafKwjLOm3j8268dFUbQ1Mudi0S1PKPkMfoQqDjwlOquQzuIaDT3prR69V-Aq3PpcU0mafqWigH8ca01P9BYO5VPN4At47FbL9-ByPwe2Pi1_nP5vrm8ur8_V1o6nEpRmwspo4zmRLpaCYO2oYcxYJ0XbSGCMY1kw5rmQnpDWi5coJTZkbqGgdpcfgy153N6X7anPpR5-1DUFFm2ruCaKMS0Lxgn5-hd6lOsX5up7gjna4Jd1CoT2l55fkybp-N_lRTY89Rv1iXf_aunnk07NwHUZr_g28eDUDzR7IamP_b31T8C9KN6Og</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2153514253</pqid></control><display><type>article</type><title>Evaluation of the rivastigmine role against botulinum toxin-A-induced osteoporosis in albino rats: A biochemical, histological, and immunohistochemical study</title><source>Sage Journals GOLD Open Access 2024</source><creator>Ali, DM ; Abdelzaher, WY ; Abdel-Hafez, SMN</creator><creatorcontrib>Ali, DM ; Abdelzaher, WY ; Abdel-Hafez, SMN</creatorcontrib><description>The present study aimed to evaluate the role of rivastigmine against the effect of a single unilateral botulinum toxin-A (BTX-A) injection on the bone and bone marrow of adult albino rats 4 weeks after injection. Twenty-four Wistar albino rats were divided into four equal groups: group I, which received distilled water; group II, which received rivastigmine (0.3 mg/kg daily, intraperitoneally for 4 weeks); group III, which received BTX-A (4 IU in 0.2 mL physiological saline) single dose, intramuscularly; and group IV, which received BTX-A + rivastigmine. The results revealed that BTX-A induced a significant decrease in the calcium level with a significant increase in the phosphorus, alkaline phosphatase, C-reactive protein, and tumor necrosis factor α levels in serum. Furthermore, a significant increase in malondialdehyde with a significant decrease in reduced glutathione activities in both bone and bone marrow. Histologically, a distortion and thinning out of the compact bone and trabeculae of cancellous bone of the rat femur in the BTX-A group with an increase in adipocytes in adjacent bone marrow were detected. Immunohistochemically, Cluster of Differentiation 68 (CD68) showed a significant increase in both osteoclasts and bone marrow macrophage. Rivastigmine treatment could relieve the toxic effects induced by BTX-A. In conclusion, rivastigmine has a protective effect against the hazardous effects of BTX-A on bone and bone marrow.</description><identifier>ISSN: 0960-3271</identifier><identifier>EISSN: 1477-0903</identifier><identifier>DOI: 10.1177/0960327118774941</identifier><identifier>PMID: 29739252</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adipocytes ; Albinism ; Alkaline phosphatase ; Animals ; Antigens, CD - metabolism ; Antigens, Differentiation, Myelomonocytic - metabolism ; Biocompatibility ; Biomedical materials ; Bone marrow ; Botulinum toxin ; Botulinum Toxins, Type A ; C-reactive protein ; Calcium ; Calcium - blood ; Cancellous bone ; Cholinesterase Inhibitors - pharmacology ; Cholinesterase Inhibitors - therapeutic use ; Distilled water ; Femur ; Femur - drug effects ; Femur - metabolism ; Femur - pathology ; Glutathione ; Glutathione - metabolism ; Immunohistochemistry ; Injection ; Macrophages ; Malondialdehyde ; Malondialdehyde - metabolism ; Osteoclastogenesis ; Osteoclasts ; Osteoporosis ; Osteoporosis - chemically induced ; Osteoporosis - drug therapy ; Osteoporosis - metabolism ; Osteoporosis - pathology ; Phosphorus ; Proteins ; Rats ; Rats, Wistar ; Rivastigmine ; Rivastigmine - pharmacology ; Rivastigmine - therapeutic use ; Toxicity ; Tumor necrosis factor-α</subject><ispartof>Human & experimental toxicology, 2018-12, Vol.37 (12), p.1323-1335</ispartof><rights>The Author(s) 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-b1aec2f7694398317f3d66fe088459ddd861c6af7a9589ed847af8c36fb384f33</citedby><cites>FETCH-LOGICAL-c391t-b1aec2f7694398317f3d66fe088459ddd861c6af7a9589ed847af8c36fb384f33</cites><orcidid>0000-0002-3177-8961 ; 0000-0001-6511-1797</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0960327118774941$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0960327118774941$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21945,27830,27901,27902,44921,45309</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/0960327118774941?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29739252$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ali, DM</creatorcontrib><creatorcontrib>Abdelzaher, WY</creatorcontrib><creatorcontrib>Abdel-Hafez, SMN</creatorcontrib><title>Evaluation of the rivastigmine role against botulinum toxin-A-induced osteoporosis in albino rats: A biochemical, histological, and immunohistochemical study</title><title>Human & experimental toxicology</title><addtitle>Hum Exp Toxicol</addtitle><description>The present study aimed to evaluate the role of rivastigmine against the effect of a single unilateral botulinum toxin-A (BTX-A) injection on the bone and bone marrow of adult albino rats 4 weeks after injection. Twenty-four Wistar albino rats were divided into four equal groups: group I, which received distilled water; group II, which received rivastigmine (0.3 mg/kg daily, intraperitoneally for 4 weeks); group III, which received BTX-A (4 IU in 0.2 mL physiological saline) single dose, intramuscularly; and group IV, which received BTX-A + rivastigmine. The results revealed that BTX-A induced a significant decrease in the calcium level with a significant increase in the phosphorus, alkaline phosphatase, C-reactive protein, and tumor necrosis factor α levels in serum. Furthermore, a significant increase in malondialdehyde with a significant decrease in reduced glutathione activities in both bone and bone marrow. Histologically, a distortion and thinning out of the compact bone and trabeculae of cancellous bone of the rat femur in the BTX-A group with an increase in adipocytes in adjacent bone marrow were detected. Immunohistochemically, Cluster of Differentiation 68 (CD68) showed a significant increase in both osteoclasts and bone marrow macrophage. Rivastigmine treatment could relieve the toxic effects induced by BTX-A. In conclusion, rivastigmine has a protective effect against the hazardous effects of BTX-A on bone and bone marrow.</description><subject>Adipocytes</subject><subject>Albinism</subject><subject>Alkaline phosphatase</subject><subject>Animals</subject><subject>Antigens, CD - metabolism</subject><subject>Antigens, Differentiation, Myelomonocytic - metabolism</subject><subject>Biocompatibility</subject><subject>Biomedical materials</subject><subject>Bone marrow</subject><subject>Botulinum toxin</subject><subject>Botulinum Toxins, Type A</subject><subject>C-reactive protein</subject><subject>Calcium</subject><subject>Calcium - blood</subject><subject>Cancellous bone</subject><subject>Cholinesterase Inhibitors - pharmacology</subject><subject>Cholinesterase Inhibitors - therapeutic use</subject><subject>Distilled water</subject><subject>Femur</subject><subject>Femur - drug effects</subject><subject>Femur - metabolism</subject><subject>Femur - pathology</subject><subject>Glutathione</subject><subject>Glutathione - metabolism</subject><subject>Immunohistochemistry</subject><subject>Injection</subject><subject>Macrophages</subject><subject>Malondialdehyde</subject><subject>Malondialdehyde - metabolism</subject><subject>Osteoclastogenesis</subject><subject>Osteoclasts</subject><subject>Osteoporosis</subject><subject>Osteoporosis - chemically induced</subject><subject>Osteoporosis - drug therapy</subject><subject>Osteoporosis - metabolism</subject><subject>Osteoporosis - pathology</subject><subject>Phosphorus</subject><subject>Proteins</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Rivastigmine</subject><subject>Rivastigmine - pharmacology</subject><subject>Rivastigmine - therapeutic use</subject><subject>Toxicity</subject><subject>Tumor necrosis factor-α</subject><issn>0960-3271</issn><issn>1477-0903</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1P3DAQhi3UqizQO6fKUi89NK0_En9wWyFKkZC4lHPk-GPXyLGX2Eblx_S_NmGhlZA4jWbmmXdG8wJwitE3jDn_jiRDlHCMBeetbPEBWOGW8wZJRN-B1dJulv4hOMr5DiHEZIc_gEMiOZWkIyvw5-JBhaqKTxEmB8vWwsk_qFz8ZvRxTlKwUG2Uj7nAIZUafKwjLOm3j8268dFUbQ1Mudi0S1PKPkMfoQqDjwlOquQzuIaDT3prR69V-Aq3PpcU0mafqWigH8ca01P9BYO5VPN4At47FbL9-ByPwe2Pi1_nP5vrm8ur8_V1o6nEpRmwspo4zmRLpaCYO2oYcxYJ0XbSGCMY1kw5rmQnpDWi5coJTZkbqGgdpcfgy153N6X7anPpR5-1DUFFm2ruCaKMS0Lxgn5-hd6lOsX5up7gjna4Jd1CoT2l55fkybp-N_lRTY89Rv1iXf_aunnk07NwHUZr_g28eDUDzR7IamP_b31T8C9KN6Og</recordid><startdate>20181201</startdate><enddate>20181201</enddate><creator>Ali, DM</creator><creator>Abdelzaher, WY</creator><creator>Abdel-Hafez, SMN</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7ST</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>SOI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3177-8961</orcidid><orcidid>https://orcid.org/0000-0001-6511-1797</orcidid></search><sort><creationdate>20181201</creationdate><title>Evaluation of the rivastigmine role against botulinum toxin-A-induced osteoporosis in albino rats: A biochemical, histological, and immunohistochemical study</title><author>Ali, DM ; Abdelzaher, WY ; Abdel-Hafez, SMN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-b1aec2f7694398317f3d66fe088459ddd861c6af7a9589ed847af8c36fb384f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adipocytes</topic><topic>Albinism</topic><topic>Alkaline phosphatase</topic><topic>Animals</topic><topic>Antigens, CD - metabolism</topic><topic>Antigens, Differentiation, Myelomonocytic - metabolism</topic><topic>Biocompatibility</topic><topic>Biomedical materials</topic><topic>Bone marrow</topic><topic>Botulinum toxin</topic><topic>Botulinum Toxins, Type A</topic><topic>C-reactive protein</topic><topic>Calcium</topic><topic>Calcium - blood</topic><topic>Cancellous bone</topic><topic>Cholinesterase Inhibitors - pharmacology</topic><topic>Cholinesterase Inhibitors - therapeutic use</topic><topic>Distilled water</topic><topic>Femur</topic><topic>Femur - drug effects</topic><topic>Femur - metabolism</topic><topic>Femur - pathology</topic><topic>Glutathione</topic><topic>Glutathione - metabolism</topic><topic>Immunohistochemistry</topic><topic>Injection</topic><topic>Macrophages</topic><topic>Malondialdehyde</topic><topic>Malondialdehyde - metabolism</topic><topic>Osteoclastogenesis</topic><topic>Osteoclasts</topic><topic>Osteoporosis</topic><topic>Osteoporosis - chemically induced</topic><topic>Osteoporosis - drug therapy</topic><topic>Osteoporosis - metabolism</topic><topic>Osteoporosis - pathology</topic><topic>Phosphorus</topic><topic>Proteins</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Rivastigmine</topic><topic>Rivastigmine - pharmacology</topic><topic>Rivastigmine - therapeutic use</topic><topic>Toxicity</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ali, DM</creatorcontrib><creatorcontrib>Abdelzaher, WY</creatorcontrib><creatorcontrib>Abdel-Hafez, SMN</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Environment Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Environment Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Human & experimental toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Ali, DM</au><au>Abdelzaher, WY</au><au>Abdel-Hafez, SMN</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the rivastigmine role against botulinum toxin-A-induced osteoporosis in albino rats: A biochemical, histological, and immunohistochemical study</atitle><jtitle>Human & experimental toxicology</jtitle><addtitle>Hum Exp Toxicol</addtitle><date>2018-12-01</date><risdate>2018</risdate><volume>37</volume><issue>12</issue><spage>1323</spage><epage>1335</epage><pages>1323-1335</pages><issn>0960-3271</issn><eissn>1477-0903</eissn><abstract>The present study aimed to evaluate the role of rivastigmine against the effect of a single unilateral botulinum toxin-A (BTX-A) injection on the bone and bone marrow of adult albino rats 4 weeks after injection. Twenty-four Wistar albino rats were divided into four equal groups: group I, which received distilled water; group II, which received rivastigmine (0.3 mg/kg daily, intraperitoneally for 4 weeks); group III, which received BTX-A (4 IU in 0.2 mL physiological saline) single dose, intramuscularly; and group IV, which received BTX-A + rivastigmine. The results revealed that BTX-A induced a significant decrease in the calcium level with a significant increase in the phosphorus, alkaline phosphatase, C-reactive protein, and tumor necrosis factor α levels in serum. Furthermore, a significant increase in malondialdehyde with a significant decrease in reduced glutathione activities in both bone and bone marrow. Histologically, a distortion and thinning out of the compact bone and trabeculae of cancellous bone of the rat femur in the BTX-A group with an increase in adipocytes in adjacent bone marrow were detected. Immunohistochemically, Cluster of Differentiation 68 (CD68) showed a significant increase in both osteoclasts and bone marrow macrophage. Rivastigmine treatment could relieve the toxic effects induced by BTX-A. In conclusion, rivastigmine has a protective effect against the hazardous effects of BTX-A on bone and bone marrow.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>29739252</pmid><doi>10.1177/0960327118774941</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-3177-8961</orcidid><orcidid>https://orcid.org/0000-0001-6511-1797</orcidid></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 0960-3271 |
| ispartof | Human & experimental toxicology, 2018-12, Vol.37 (12), p.1323-1335 |
| issn | 0960-3271 1477-0903 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2036792313 |
| source | Sage Journals GOLD Open Access 2024 |
| subjects | Adipocytes Albinism Alkaline phosphatase Animals Antigens, CD - metabolism Antigens, Differentiation, Myelomonocytic - metabolism Biocompatibility Biomedical materials Bone marrow Botulinum toxin Botulinum Toxins, Type A C-reactive protein Calcium Calcium - blood Cancellous bone Cholinesterase Inhibitors - pharmacology Cholinesterase Inhibitors - therapeutic use Distilled water Femur Femur - drug effects Femur - metabolism Femur - pathology Glutathione Glutathione - metabolism Immunohistochemistry Injection Macrophages Malondialdehyde Malondialdehyde - metabolism Osteoclastogenesis Osteoclasts Osteoporosis Osteoporosis - chemically induced Osteoporosis - drug therapy Osteoporosis - metabolism Osteoporosis - pathology Phosphorus Proteins Rats Rats, Wistar Rivastigmine Rivastigmine - pharmacology Rivastigmine - therapeutic use Toxicity Tumor necrosis factor-α |
| title | Evaluation of the rivastigmine role against botulinum toxin-A-induced osteoporosis in albino rats: A biochemical, histological, and immunohistochemical study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T08%3A57%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20rivastigmine%20role%20against%20botulinum%20toxin-A-induced%20osteoporosis%20in%20albino%20rats:%20A%20biochemical,%20histological,%20and%20immunohistochemical%20study&rft.jtitle=Human%20&%20experimental%20toxicology&rft.au=Ali,%20DM&rft.date=2018-12-01&rft.volume=37&rft.issue=12&rft.spage=1323&rft.epage=1335&rft.pages=1323-1335&rft.issn=0960-3271&rft.eissn=1477-0903&rft_id=info:doi/10.1177/0960327118774941&rft_dat=%3Cproquest_AFRWT%3E2036792313%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2153514253&rft_id=info:pmid/29739252&rft_sage_id=10.1177_0960327118774941&rfr_iscdi=true |